Kanagaratnam Jegathesan, MD
Internal Medicine · Waterbury, CTNPI 1497859409
Payments from drug & device makers
Across 55 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$210
- Novo Nordisk$174
- Boehringer Ingelheim$93
- Exact Sciences$92
- Astellas Pharma US Inc$88
- AbbVie$70
- plus $509 from 17 others
What the payments were for
- Food & beverage$1,236100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 9 | $210 |
| Novo Nordisk | 8 | $174 |
| Boehringer Ingelheim | 5 | $93 |
| Exact Sciences | 3 | $92 |
| Astellas Pharma US Inc | 3 | $88 |
| AbbVie | 3 | $70 |
| GSK | 3 | $61 |
| Mylan Specialty L.p. | 3 | $57 |
| Abbott | 2 | $49 |
| Pfizer | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Bayer | 1 | $34 |
| AstraZeneca | 1 | $30 |
| Lundbeck LLC | 1 | $29 |
| Amgen | 1 | $23 |
| Merck | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
How this compares
$1,236 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 154 | $111,859 |
| JardianceEmpagliflozin | 101 | $108,509 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $98,179 |
| MounjaroTirzepatide | 65 | $84,920 |
| RybelsusSemaglutide | 55 | $69,979 |
| JanuviaSitagliptin Phosphate | 52 | $61,758 |
| OzempicSemaglutide | 53 | $49,193 |
| FarxigaDapagliflozin Propanediol | 38 | $48,993 |
| XareltoRivaroxaban | 60 | $42,321 |
| TrulicityDulaglutide | 32 | $31,342 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $19,351 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $16,864 |
| LinzessLinaclotide | 21 | $11,672 |
| VraylarCariprazine Hcl | 11 | $11,163 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $7,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $174 | $119,172108 claims |
| Lilly USA, LLCMounjaro, Trulicity | $210 | $116,26297 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $61 | $115,043149 claims |
| Boehringer IngelheimJardiance, Tradjenta | $93 | $112,173115 claims |
| PfizerEliquis | $42 | $111,859154 claims |
| MerckJanuvia, Janumet, Dulera | $22 | $87,31392 claims |
| AstraZenecaFarxiga, Symbicort | $30 | $56,89557 claims |
| AbbVieLinzess, Vraylar, Restasis, Synthroid | $70 | $33,92286 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $20 | $7,04716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Waterbury
- Joseph SouferWaterbury$21.5M
- Elie HelouWaterbury$184K
- Oltjon AlbajramiWaterbury$57K
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.